Breaking News, Collaborations & Alliances

Avanir, OptiNose in Drug Delivery Pact

To use OptiNose delivery system for migraine treatment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Avanir Pharmaceuticals and OptiNose AS have entered into an exclusive North American license agreement for the development and commercialization of OptiNose’s Breath Powered intranasal delivery system containing sumatriptan powder to treat acute migraine. OptiNose received an upfront cash payment of $20 million and is eligible to receive as much as an additional $90 million in clinical, regulatory and commercial milestones. If approved, OptiNose will also receive royalties on sales.   Avan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters